鱼跃医疗发布股份回购计划，前十大股东持股情况曝光

【2026年5月27日，江苏】 江苏鱼跃医疗设备股份有限公司（以下简称“鱼跃医疗”或“公司”，股票代码：002223）于2026年5月22日召开第六届董事会第十七次临时会议，审议并通过了《关于回购公司股份并用于注销的议案》，计划以自有资金回购部分股份并用于注销。这一举措体现了公司对其内在价值和未来发展的信心，并可能对公司股价产生积极影响。

一、回购股份计划的关键内容

• 回购议案已于2026年5月22日董事会审议通过，并于2026年5月23日在巨潮资讯网公开披露。
• 回购股份将用于注销，有助于优化公司股本结构，提升每股收益，反映公司对未来发展的信心。

二、前十大股东持股情况（截至2026年5月22日）

公司在公告中详细披露了回购决议前一个交易日登记在册的前十大股东及其持股数量、占比情况，具体如下：

三、前十大无限售条件流通股股东持股情况

除了前十大总股东，公司还披露了前十大无限售条件流通股股东的持股详情，主要持股情况如下：

• 江苏鱼跃科技发展有限公司持有2.46亿股，占无限售流通股26.05%
• 吴光明持有1.03亿股，占10.95%
• 香港中央结算有限公司持有3408万股，占3.61%
• 全国社保基金一一三组合持有2941万股，占3.11%
• 基本养老保险基金八零二组合持有2187万股，占2.32%
• 中国银行股份有限公司-华宝中证医疗ETF持有2077万股，占2.20%
• 吴群持有1934万股，占2.05%
• 全国社保基金一零二组合、基本养老保险基金一二零一组合和二零零九组合均在1%上下

四、事件对投资者和股价的潜在影响

• 股份回购与注销：公司计划回购股份并注销，属于典型的利好消息。此举将减少公司总股本，提升每股盈利能力，并显示公司管理层对未来业绩及价值的高度信心，历史经验来看，类似举措常常对股价形成正面刺激。
• 主要股东结构稳定：江苏鱼跃科技发展有限公司、吴光明、吴群等核心股东和机构投资者依旧稳居前列，显示大股东持股稳定，有助于增强市场信心。
• 机构投资者高度参与：社保基金、养老保险基金、ETF等机构持股占比较高，表明公司获得了主流机构的高度认可。

五、投资者应关注事项

1. 回购规模、价格区间及后续进展公告，可能持续影响市场情绪。
2. 大股东持股未见明显变化，若后续有增减持动态，需密切关注。
3. 公司回购行为显示出资金实力和经营自信，若回购顺利实施，有望提升二级市场估值。

六、备查文件

本次公告所依据的股东名册由中国证券登记结算有限责任公司深圳分公司出具，确保数据权威、准确。

总结

本次股份回购及注销计划，结合稳定的股东结构、主流机构的高度参与，对公司基本面和市场情绪都形成实质利好，或将成为股价上涨的催化剂。投资者应密切关注后续回购实施进度及相关信息披露动态。

免责声明： 本文仅为信息披露与市场分析，不构成任何投资建议。投资有风险，入市需谨慎，投资者请结合自身实际情况做出独立判断。

English Version

Yuyue Medical Announces Share Repurchase Plan and Discloses Top 10 Shareholders

[May 27, 2026, Jiangsu] Jiangsu Yuyue Medical Equipment Co., Ltd. (“Yuyue Medical” or “the Company”, Stock Code: 002223) held its 17th interim session of the 6th Board of Directors on May 22, 2026, where it approved a plan to repurchase a portion of its shares with self-owned funds for subsequent cancellation. This move underscores the Company’s confidence in its intrinsic value and future prospects and may have a positive impact on its share price.

1. Key Points of the Repurchase Plan

• The repurchase proposal was approved on May 22, 2026, and disclosed on May 23, 2026, via cninfo.com.cn.
• Repurchased shares will be cancelled, optimizing share capital structure and improving EPS, reflecting management’s confidence in the future.

2. Top 10 Shareholders as of May 22, 2026

The Company disclosed its top 10 shareholders and their holdings before the repurchase resolution:

3. Top 10 Holders of Unrestricted Shares

The Company also disclosed the top 10 holders of unrestricted circulating shares:

• Jiangsu Yuyue Technology Development Co., Ltd.: 245.98 million shares (26.05%)
• Wu Guangming: 103.43 million shares (10.95%)
• Hong Kong Securities Clearing Company: 34.08 million shares (3.61%)
• National Social Security Fund 113 Portfolio: 29.41 million shares (3.11%)
• Basic Pension Fund 802 Portfolio: 21.87 million shares (2.32%)
• BANK OF CHINA-HuaBao CSI Medical ETF: 20.77 million shares (2.20%)
• Wu Qun: 19.34 million shares (2.05%)
• Other institutional investors each hold around 1%.

4. Potential Impacts on Investors and Share Price

• Share Repurchase and Cancellation: The plan to repurchase and cancel shares is generally viewed as positive, as it reduces total share capital, increases earnings per share, and signals strong management confidence—typically supporting share price performance.
• Stable Major Shareholders: The largest shareholders remain stable, indicating confidence and long-term commitment, which is reassuring for the market.
• High Institutional Participation: Heavy involvement of social security, pension funds, and ETFs demonstrates strong recognition from major institutional investors.

5. Matters for Investors to Watch

1. Details on repurchase size, price range, and follow-up progress, as further news may affect market sentiment.
2. Any changes in major shareholder holdings post-repurchase should be closely monitored.
3. The repurchase action demonstrates financial strength and management confidence that, if executed, could boost market valuation.

6. Reference Documents

The shareholder register was provided by the Shenzhen branch of China Securities Depository and Clearing Corporation, ensuring the data’s authority and accuracy.

Conclusion

Yuyue Medical’s share repurchase and cancellation plan, alongside stable shareholder structure and strong institutional participation, sends a clear positive signal about its fundamentals and outlook—potentially serving as a catalyst for share price appreciation. Investors should closely follow subsequent disclosures and implementation progress of the buyback.

Disclaimer: The above content is for information disclosure and market analysis only and does not constitute investment advice. Investment involves risk. Please make independent investment decisions based on your own circumstances.

View 鱼跃医疗 Historical chart here